Skip to content

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Icotrokinra, a Targeted Oral Peptide, in Participants With Moderate-to-Severe Plaque Psoriasis and Self-Reported Psoriatic Arthritis: Results From a Pooled Analysis of the Phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 Trials

Background Icotrokinra, a targeted oral peptide that precisely blocks the interleukin-23 receptor, is approved to treat adult and pediatric (≥12 years, ≥40 kg) patients with moderate-to-severe plaque psoriasis (PsO). Objective Assess psoriatic arthritis (PsA)–specific outcomes through Week (W) 16 in a subgroup of phase...

I. McInnes, L. Stein-Gold, R. Bissonnette et al. · 0 citations
Open access Oct 2026

Bimekizumab efficacy across GRAPPA domains to 3 years in patients with psoriatic arthritis: a post hoc analysis of two phase 3 studies.

OBJECTIVES To evaluate the long-term efficacy of bimekizumab in patients with psoriatic arthritis (PsA) across the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) domains, PsA-related conditions, and comorbidities. METHODS Post hoc analysis of pooled data from BE OPTIMAL (NCT03895203;...

A. Deodhar, Alice B. Gottlieb, J. Merola et al. · 0 citations
Open access Oct 2026

Long-Term Safety and Efficacy of Upadacitinib in Patients with Psoriatic Arthritis: 5-Year Results from the Phase 3 SELECT-PsA 1 Study.

INTRODUCTION In the phase 3 SELECT-PsA 1 study, treatment with upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, improved signs and symptoms of psoriatic arthritis (PsA) from weeks 12 through 152. We now report the long-term extension phase, evaluating safety and efficacy of upadacitinib versus adalimumab (ADA)...

I. McInnes, Koji Kato, Marina N. Magrey et al. · 0 citations
Open access Jul 2026

Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2

Abstract Objective This post hoc analysis of the SELECT-PsA 2 study evaluated long-term efficacy and safety of upadacitinib 15 mg once daily in patients with psoriatic arthritis (PsA) and exposure to one prior tumour necrosis factor inhibitor (TNFi). Methods Patients were randomised to upadacitinib 15 mg once daily or...

L. Coates, P. Mease, A. Kavanaugh et al. · 0 citations
Open access Jul 2026

Inflammatory marker profiles vary by BMI across Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis

Background Obesity represents a state of chronic low-grade inflammation, yet comprehensive comparative analyses examining systemic inflammatory markers across multiple immune-mediated inflammatory diseases (IMIDs) in relation to body mass index (BMI) categories remain limited. We evaluated how obesity-associated inflam...

Stephen A. Shields, Ann Von Holle, R. Padival et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.